Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy

NCT01165684 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01165684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01165684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2010
Completion date
April 30, 2012
Enrollment
401 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2